Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial
| Autor: | D. Bacca, Mauro Annese, Filippo Matarazzo, Giuseppe Barbaro, Gaetano Scotto, Marcello Bruno, Giorgio Barbarini, Gabriele Di Stefano, Ruggiero Francavilla, Franco Zechini, Sergio Babudieri, Adriano M. Pellicelli |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male medicine.medical_specialty Hepatitis B virus Randomization Combination therapy Alpha interferon Interferon alpha-2 Gastroenterology Antiviral Agents law.invention Pharmacotherapy Hepatitis B Chronic Randomized controlled trial law Internal medicine medicine Humans Interferon alfa Hepatitis B Surface Antigens Hepatology business.industry Lamivudine Interferon-alpha Alanine Transaminase Hepatitis B Middle Aged medicine.disease Recombinant Proteins Surgery DNA Viral Mutation Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Journal of hepatology. 35(3) |
| ISSN: | 0168-8278 |
| Popis: | Background/Aims : To evaluate the therapeutic efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. Methods : One hundred and fifty-one patients were randomly assigned to receive either recombinant interferon alpha-2b (nine million units three times per week) and lamivudine (100mg/daily per os) for 24 weeks or lamivudine alone (100mg/daily per os) for 52 weeks. Patients were followed up for a further 48 weeks. Results : Sustained HBeAg seroconversion with undetectable serum levels of HBV DNA was observed in 25 of 76 patients (33%) treated with the combination therapy and in 11 of 75 patients (15%) treated with monotherapy ( P =0.014). Histological improvement defined as a reduction of at least two points in the inflammation score as compared with pretreatment score was observed in 35 of 76 patients (46%) treated with combination therapy and in 20 of 75 patients (27%) treated with monotherapy ( P =0.021). Both therapeutic regimens were well tolerated. Conclusions : Six-month treatment with interferon alpha-2b and lamivudine in combination appeared to increase the rate of sustained HBeAg seroconversion compared to 1-year lamivudine monotherapy. However, the potential benefit of combining lamivudine and interferon should be investigated further in studies with different regimens of combination therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect